Compounds > trovafloxacin
Page last updated: 2024-08-24

trovafloxacin and Bacteroides Infections

trovafloxacin has been researched along with Bacteroides Infections in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's3 (60.00)18.2507
2000's2 (40.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Goldstein, EJ1
Cimochowski, CR; Faiella, JA; Girard, AE; Girard, D; Gootz, TD1
Brown, P; Chuah, SK; Esfandiari, A; Gollapudi, S; Hanna, N; Malilay, C; Polzer, RJ; Reddy, U; Thadepalli, F; Thadepalli, H1
Chuah, SK; Clark, R; Gollapudi, S; Hanna, N; Polzer, RJ; Reddy, U; Thadepalli, H1
Goessens, WH; Gyssens, IC; Mouton, JW; Oyen, WJ; Stearne, LE; van der Meer, JW; Verbrugh, HA1

Other Studies

5 other study(ies) available for trovafloxacin and Bacteroides Infections

ArticleYear
Intra-abdominal anaerobic infections: bacteriology and therapeutic potential of newer antimicrobial carbapenem, fluoroquinolone, and desfluoroquinolone therapeutic agents.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2002, Sep-01, Volume: 35, Issue:Suppl 1

    Topics: Abdominal Abscess; Anti-Bacterial Agents; Aza Compounds; Bacteremia; Bacteria, Anaerobic; Bacteroides fragilis; Bacteroides Infections; beta-Lactams; Carbapenems; Clinical Trials as Topic; Ertapenem; Fluoroquinolones; Gemifloxacin; Humans; Indoles; Lactams; Moxifloxacin; Naphthyridines; Quinolines; Quinolones

2002
In vivo efficacy of trovafloxacin (CP-99,219), a new quinolone with extended activities against gram-positive pathogens, Streptococcus pneumoniae, and Bacteroides fragilis.
    Antimicrobial agents and chemotherapy, 1995, Volume: 39, Issue:10

    Topics: Animals; Anti-Infective Agents; Bacteroides fragilis; Bacteroides Infections; Escherichia coli Infections; Female; Fluoroquinolones; Male; Mice; Naphthyridines; Pneumococcal Infections

1995
In vivo efficacy of trovafloxacin (CP-99,217), a new quinolone, in experimental intra-abdominal abscesses caused by Bacteroides fragilis and Escherichia coli.
    Antimicrobial agents and chemotherapy, 1997, Volume: 41, Issue:3

    Topics: Abdominal Abscess; Animals; Anti-Infective Agents; Bacteroides fragilis; Bacteroides Infections; Escherichia coli; Escherichia coli Infections; Fluoroquinolones; Male; Microbial Sensitivity Tests; Naphthyridines; Rats; Rats, Sprague-Dawley; Tumor Necrosis Factor-alpha

1997
Efficacy of trovafloxacin for treatment of experimental Bacteroides infection in young and senescent mice.
    Antimicrobial agents and chemotherapy, 1997, Volume: 41, Issue:9

    Topics: Abdominal Abscess; Aging; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Bacteroides Infections; Clindamycin; Fluoroquinolones; Male; Mice; Naphthyridines; Tissue Distribution

1997
In vivo efficacy of trovafloxacin against Bacteroides fragilis in mixed infection with either Escherichia coli or a vancomycin-resistant strain of Enterococcus faecium in an established-abscess murine model.
    Antimicrobial agents and chemotherapy, 2001, Volume: 45, Issue:5

    Topics: Abscess; Animals; Anti-Infective Agents; Bacteroides fragilis; Bacteroides Infections; Blood Proteins; Disease Models, Animal; Enterococcus faecium; Escherichia coli; Escherichia coli Infections; Female; Fluoroquinolones; Gram-Positive Bacterial Infections; Immunoglobulin G; Mice; Mice, Inbred BALB C; Naphthyridines; Treatment Outcome; Vancomycin Resistance

2001